Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 22

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 22
---
 the Board of Directors and facilitating the annual Board of Directors assessment process. 12 Committees of the Board of Directors Our Board of Directors has established an Audit Committee, Compensation Committee and Governance and Nominating Committee. Our Board of Directors approved our Audit Committee, Compensation Committee and Governance and Nominating Committee charters, under which the respective committees operate. Audit Committee The current members of our Audit Committee are Mr. Hudson, who is the Chair of the committee, Dr. Gemayel, and Ms. Sensenig. All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and The Nasdaq Stock Market. Our Board of Directors has determined that each of Mr. Hudson and Ms. Sensenig is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of The Nasdaq Stock Market, in the case of Mr. Hudson, as a result of his experience as a partner in the accounting firm of KPMG LLP and his service as chair of the audit committee of other companies, and in the case of Ms. Sensenig, as a result of her experience serving as Chief Financial Officer of several private and public companies. Mr. Hudson, Dr. Gemayel, and Ms. Sensenig are independent directors as defined under the applicable rules and regulations of the SEC and The Nasdaq Stock Market. The Audit Committee held five (5) meetings during the last fiscal year. The Audit Committee operates under a written charter that satisfies the applicable standards of the SEC and The Nasdaq Stock Market and is currently available at ir.supernus.com/corporate-governance. Our Audit Committee’s responsibilities include: • discussing with management and the independent auditors the audited financial statements, the results of the annual audit and the review of our quarterly financial statements; • discussing with management, internal auditors, and independent auditors the quality and adequacy of our internal controls, and internal auditing procedures; • reviewing a summary of expenses of all our officers, as defined in Section 16 of the Securities Exchange Act of 1934, as amended, and review on a periodic basis any expenses not currently contemplated by our internal expense policy; • discussing with management, the internal auditors and the independent auditors the significant risks and exposures facing the Company and related risk mitigation plans; • serving as the Board of Director’s primary body to oversee risk identification, management, and mitigation strategies related to cybersecurity related information technology